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B
ackground to the debate: The World Health Organization 
(WHO) and its partners aim to treat 3 million people 
infected with HIV in poor and middle income countries with 
antiretroviral treatment by the end of 2005. The ambitious “3 
by 5” initiative has had its supporters and its critics since its 
announcement in 2002.
Jim Yong Kim’s Viewpoint: 3 by 5 is a Point of 
Entry, Not an End in Itself
There are no sure prescriptions against great plagues 
like HIV. We must “learn by doing,” quickly assessing the 
inevitable missteps and false starts and using this information 
to improve outcomes. Our best information about the HIV 
pandemic suggests four clear principles. 
First, treatment must be a core element. This does not 
mean treatment alone. Antiretroviral therapy (ART) is 
in no way more important than education, prevention of 
mother-to-child transmission, expanded access to testing 
and counseling, or other pieces of a comprehensive public 
health effort. But preventing mother-to-child transmission is a 
pyrrhic victory if, as the latest data suggest, AIDS will cause 15 
million of those uninfected children to grow up as orphans 
[1]. Education is fruitless when the hope of ﬁ  nding work has 
disappeared because the loss of so many productive workers 
has led to the near collapse of industrial enterprise [2]. The 
dramatic beneﬁ  ts of ART for patients with advanced HIV 
disease (“the Lazarus effect”) engage the public imagination, 
helping to build political will on behalf of all interventions 
against the pandemic. And treatment can accelerate 
prevention by offering an incentive to get tested and know 
one’s status, by reducing the stigma of an infection that leads 
to certain death, and by giving health workers credibility in 
devastated communities. Treatment is a point of entry, not an 
end in itself.
Second, time is of the essence. Every data point in the arcs 
of HIV transmission, morbidity, and mortality represents 
an exponential increase in human suffering and social and 
economic disruption. Countries that were able to respond 
early and comprehensively to HIV now have mortality rates 
comparable to those of Europe and North America and 
have cut transmission dramatically. Early interventions can 
provide large cost savings to the public sector and prevent 
devastating losses of human capital [3]. There may be risks 
associated with rapid scale-up—promotion of drug resistance 
or implementation of care delivery models that are not a 
perfect ﬁ  t in all settings [4]. It is essential that we manage 
these risks through effective monitoring, evaluation, “real 
time” operational research, and knowledge management. 
However, the risks of action are minor compared with the 
certain failings of deferral.
Third, clear consensus targets are indispensable. An 
effective response to HIV demands the resources and 
attention of every region, state, and community. Coordinating 
these many different stakeholders requires clarity of purpose. 
All the great public projects of the modern era, such as the 
ﬁ  rst manned moon expeditions of the 1960s, began with the 
establishment of a ringing collective priority. Like the 3 by 
5 initiative, these projects were in themselves only surrogate 
endpoints. But they provided focus for the energies of their 
many participants. To reach the ultimate goal of universal 
access to ART we must plan in stages.
Fourth, the speciﬁ  c procedures developed to combat 
HIV must be codiﬁ  ed and simpliﬁ  ed. Because pandemics, 
by deﬁ  nition, afﬂ  ict communities with a broad range of 
material resources and technical capacities, our methods 
must be suitable to the most disrupted and impoverished of 
them. This means effective training modules to increase the 
supply of health workers; it means inexpensive, rapid tests 
and diagnostics; and it means streamlined regimens and 
ﬁ  xed-dose combinations that facilitate drug procurement and 
improve rates of adherence.
These principles are at the heart of the 3 by 5 effort. When 
it was announced in 2002, the gap between the damned and 
the saved had ﬁ  nally begun to narrow after sharp declines 
in the price of ART and the emergence of large-scale 
ﬁ  nancing through the Global Fund, the World Bank, and the 
President’s Emergency Plan for AIDS Relief. AIDS is unusual 
in the history of epidemics because proven, effective ways 
of interrupting the course of the disease have existed since 
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shortly after its emergence, yet those methods were foreclosed 
to most of the world’s population. The announcement of 3 by 
5 drew from a widespread sense that this inequality presented 
unacceptable economic, political, moral, and epidemiological 
consequences.
Scaling up treatment is not only a possibility, but is already 
a reality. The number of patients on ART has nearly doubled 
in the last two years, mostly in countries where therapy had 
been limited to a privileged few [5]. High-burden countries 
are doing their part; the rest of the world must now share 
more fully in combating the pandemic. From sterile debates 
over prevention and treatment, the task has shifted to 
upgrading health systems in resource-poor settings to permit 
a comprehensive response to the epidemic. 
Those who object to 3 by 5 must address this question: 
what would be the likely cost if it were never attempted? We 
can work exclusively to prevent the further spread of HIV, 
or aim to improve treatment access more slowly, but in the 
meanwhile high-burden countries will collapse at our feet. Or 
we can aim for 3 by 5 and move ourselves that much closer 
to the ultimate goal: preventing all unnecessary deaths from 
HIV.
Arthur Ammann’s Viewpoint: The Intentions Are 
Good, the Approach Is Wrong
There is much that is exemplary about the basic principles 
outlined by WHO for treatment expansion. Improving access 
to life-saving ART is a moral imperative and everyone agrees 
that this will take lots of money [6,7]. So where is the debate?
The debate lies in the strategy. Reviewing the epidemic 
over the past 20 years, you would have to conclude that the 
current international public health approach has failed 
and that an urgent change is required. There are three 
fundamental problems with the 3 by 5 approach.
First, it is very narrow, and narrow strategies for tackling 
HIV often fail. For example, we have known for ﬁ  ve 
years that a single dose of nevirapine can help prevent 
perinatal HIV transmission. The intervention is simpler 
and cheaper than the 3 by 5 initiative—yet today less than 
5% of pregnant women infected with HIV receive any ART 
[8,9]. WHO should instead focus on a credible overarching 
public health approach that is commensurate with the 
severity of the epidemic. Sound global public health policy 
requires accountability that respects the right of individuals 
to be protected from fatal infections. This can only be 
accomplished by universal offering of HIV testing, integration 
of HIV prevention and treatment into all health-care arenas, 
contact tracing, and treatment for all who require ART 
[8,10]. The 3 by 5 initiative fully addresses only one of these 
issues—treatment—and leaves HIV-exposed individuals at 
risk for infection and infected contacts unaware of treatment 
possibilities. These are irreversible missed opportunities and 
represent a non-accountable approach to an out-of-control 
epidemic.
Second, confusion about realistic costs, sources of funding, 
and the relation to other critical WHO initiatives abound. 
Initial WHO estimates of $5 billion annually for the cost of 
the entire 3 by 5 initiative have been revised upward to $6 
billion annually [6,7,11]. It is not clear whether the costs for 
this program are distinct from other WHO initiatives, are 
incorporated into the Global Fund, will increase dramatically 
and continue beyond 2006, or are ultimately incorporated 
into national budgets. If the true cost is $6 billion annually, 
this is $2,000 per individual per year, which is surely not 
sustainable for resource-poor countries. Further, of the 40 
million individuals infected with HIV worldwide, it is likely 
that at least 20 million will require treatment, and there will 
be millions more newly diagnosed patients [11]. This would 
conservatively place treatment costs at over $40 billion per 
year. Only recently has WHO acknowledged what everyone 
else seemed to know from the beginning—it will take 
huge investments in infrastructure to sustain ART delivery 
[7,12,13,14].
Third, the 3 by 5 initiative is a “top down” unsustainable 
approach that, without a high level of government 
investment, fosters dependence on international aid. 
Countries that have taken ownership of their HIV programs 
have often been the most successful in tackling the epidemic 
[8,14,15]. Brazil has mounted an effective response to 
the HIV epidemic whereas South Africa has not. A key 
difference between these countries is that 84% of Brazil’s 
AIDS programs are funded from domestic sources compared 
to 0.4% in South Africa [6]. Furthermore, there are 
thousands of nongovernmental organizations, clinics, and 
hospitals already treating patients with HIV and a “top down” 
approach doesn’t work for these organizations. Many are 
up and running and require only minimal training to move 
ART distribution forward. The last thing they need is more 
internationally imposed hurdles that ensure sequestration of 
ART in costly and inefﬁ  cient bureaucracies.
The HIV epidemic is the worst pandemic in history. Why, 
then, is the international public health response so disparate 
from public health responses to other life-threatening 
infectious diseases? The 3 by 5 initiative, with no requirement 
for contact tracing, does not ensure the right of uninfected 
individuals to be protected or of infected contacts to gain 
access to treatment. It is time to acknowledge that the severity 
of the epidemic requires universal offering of HIV testing and 
counseling, contact tracing, and integration of sound public 
health prevention and treatment principles into all health-
care delivery systems [8,10]. 
DOI: 10.1371/journal.pmed.0010037.g002
Prevention efforts—including education—must be at the heart of 
tackling HIV 
(Photo: Rick Maiman, on behalf of the David and Lucile Packard 
Foundation)
November 2004  |  Volume 1  |  Issue 2  |  e37PLoS Medicine  |  www.plosmedicine.org 099
Thousands of existing and new teams of health-care 
workers should be trained in voluntary testing and 
counseling, and in treatment, using streamlined training 
courses. Mobile teams could be used to reach rural areas 
where as many as 50% of infected individuals may live. 
Cumbersome “top down” training and certiﬁ  cation, as is 
currently planned, will only delay the very therapy that WHO 
seeks to make more available [8,14,15].
It is a paradox that HIV is one of the few diseases that is 
deemed to require exceptional international and national 
bodies overseeing access to medicines. The success of ART 
in developed countries was a result of making ART directly 
available to those who treat patients, not to governments. 
Widespread and timely access can only occur when health 
workers are able to provide ART without repressive 
procedures. We can distribute drugs more freely for other 
diseases—why not HIV? 
Kim’s Response to Ammann’s Viewpoint
I agree with Arthur Ammann that the response of the 
international community to the HIV epidemic over the last 
20 years has been grossly inadequate. I also agree that a 
more effective strategy must pay close attention to mother-to-
child transmission, provide “opt out” testing and counseling 
integrated into key health-care settings, implement effective 
partner referral strategies, and train many thousands of 
health-care workers. These are stated WHO priorities—
integral to the 3 by 5 initiative—as any attempt to investigate 
our position would reveal [16,17]. 
Dr. Ammann’s other charges are also puzzling. Our 
latest cost projections (which he cites) in fact provide a two-
year, not annual, range of $5.1 to $5.9 billion, depending 
on the price of drugs [7]. The accusation of a “top down” 
approach seems misplaced. WHO’s primary contact is 
indeed with ministries of health, given our constitutionally 
mandated obligation to provide technical assistance for 
192 WHO member states. But I strongly dispute that this 
relationship somehow prejudices the 3 by 5 agenda against 
nongovernmental organizations or local providers. WHO 
is far from the only partner in this struggle, and we actively 
promote broad-based collaborations within the nonproﬁ  t 
sector, the private sector, among traditional healers, and 
within civil society [18].
Finally, I must point out a contradiction in Dr. Ammann’s 
arguments. On the one hand, he urges high-burden countries 
to take ownership of their HIV programs and ﬁ  nance 
these themselves. On the other, he acknowledges that if 
the “true cost [of ART] is $6 billion annually, this is $2,000 
per individual per year, which is surely not sustainable for 
resource-poor countries.” The crucial question is whether $6 
billion annually is “sustainable” for the world community as a 
whole. In facing the worst health disaster in several centuries, 
we simply cannot wait for the poorest countries to self-ﬁ  nance 
HIV treatment—or else we will be guilty of standing idly by as 
millions die and societies collapse. 
Ammann’s Response to Kim’s Viewpoint
There are time-tested prescriptions for halting epidemics, 
and HIV should be no exception. But “HIV exceptionalism” 
persists [19]. Current public health efforts fail to insist on 
universal HIV testing and contact tracing, thereby limiting 
treatment and prevention opportunities and contributing 
to “feminization” of the epidemic (more and more women 
getting infected at an earlier age) [20]. Prevention and 
treatment are inextricably linked. The 3 by 5 initiative should 
meet the high standards—individual and organizational 
accountability, justice, and public good—of other public 
health approaches.
Prevention of perinatal HIV transmission cannot be called 
a victory—not even a pyrrhic one—since less than 5% of 
pregnant women infected with HIV receive any ART. Further, 
in most perinatal HIV prevention programs sexual partners 
are generally not identiﬁ  ed, treatment has only recently 
been offered, and HIV testing has not been universally 
implemented. Narrowly focused, top-down programs such as 
the 3 by 5 initiative face similar outcomes when they adopt 
yet another partial approach that is not fully integrated into 
countrywide general health care.
The 3 by 5 initiative suggests that treatment is the 
major incentive for HIV testing. But getting tested has two 
incentives—treatment and prevention. Knowing one’s HIV 
status is a means of saving lives, an incentive that should 
motivate every individual to be tested even when treatment is 
not available. We will destine ourselves to an ever-escalating 
epidemic if we delay universal testing until treatment is 
available.
Both Jim Yong Kim and I want to treat 3 million individuals 
infected with HIV and more, and we agree that time is of 
the essence. But why take another decade to learn what we 
already know from epidemics such as tuberculosis?  Lateral, 
comprehensive approaches that equip health-care workers 
with testing and the required drugs work best [21,22]. 
Procedures to combat HIV have already been simpliﬁ  ed by 
such workers in resource-poor areas—so get the tests and the 
drugs to them and they will do the treating. 
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